performance and safety of class iib md celegyn® in vva

Conditions: Vulvovaginal Atrophy

Summary: the aim of this study is primarily to investigate the performance of celegyn®, a hyaluronic acid-based vaginal cream (ce marked 0546 medical device), enriched with plant-based ingredients, in comparison with placebo, in promoting vaginal health in adult woman reporting symptoms of vulvovaginal atrophy - vva (or atrophic vulvovaginitis)


Eligibility criteria:
inclusion criteria: 1. female patients aged between 18 and 65 years. 2. patients reporting vulvovaginal dryness associated with spontaneous pain and / or dyspareunia (minimum score of 30 on a 100 mm visual analogue scale for both symptoms referable to vulvovaginal atrophy: dryness and spontaneous pain and / or dyspareunia). 3. patients sexually active (i.e. women who currently have intercourse or other sexual activity (masturbation, etc) at least once a month (with or without a partner), or who had intercourse or other sexual activity at least once a month in the past, but later decreased sexual activity due to excessive pain or vaginal dryness. dyspareunia is defined (2nd international consultation on sexual medicine) as "persistent or recurrent pain with attempted or complete vaginal entry and/or penile vaginal intercourse" that is not the result of other abnormalities). 4. patients agreeing not to use lubricants or other topically applied vaginal products during the study and not to modify their personal hygiene products. 5. patients of childbearing potential following a reliable (according to investigator's opinion) non-hormonal contraception therapy. 6. patients presenting body mass index between 18.5 and 29.9 kg/m2. 7. patients with normal papanicolaou test results (including inflammatory changes) within the past 12 months after specimen collection. 8. willingness to participate in the study and to sign an informed consent form. 9. no past or present narcotic addiction or alcoholism. exclusion criteria: 1. patients presenting vulvar or vaginal pathology other than vulvovaginal atrophy. 2. patients pregnant or breastfeeding. 3. patients presenting undiagnosed abnormal genital bleeding. 4. patients presenting endometrial pathology, such as hyperplasia (endometriosis) or endometrial polyps, cancer, palpable fibroids or grade 2 uterine prolapse (when the cervix reaches the labia minora) on gynaecologic examination. 5. patients presenting coagulation disorders or on anticoagulant drug therapy (except clopidogrel or acetylsalicylic acid). 6. patients diagnosed with clinically significant metabolic or endocrine disease or diabetes mellitus uncontrolled by medication. 7. patients diagnosed with hypertension and in treatment with antihypertensive medications. 8. patients diagnosed with severe renal and/or hepatic insufficiency. 9. patients who have changed or started systemic oestrogen - progestin or hormone therapy in the 3 months prior to inclusion (including contraceptive therapy (pill) or substitutive hormonal therapy (sht)). 10. patients on systemic chronic oestrogen - progestin therapy (including contraceptive therapy (pill) or substitutive hormonal therapy (sht)). 11. patients in treatment with the following systemic drug: nonsteroidal anti-inflammatory drugs, antihistamines, corticosteroids in the 2 weeks prior to inclusion, immunosuppressants in the 3 months prior to inclusion, venotonic or diuretic agents in the month prior to inclusion. 12. patients using topic oestrogen - progestin or hormonal therapy, in the week prior to inclusion. 13. patients in treatment with topically applied vaginal products, including medications to promote healing, in the week prior to inclusion. 14. patients that participated in any other clinical trial during the last month or participating in any clinical trial while participating in this trial. 15. patients reporting allergy or intolerance to any component of test product, placebo or rescue product. 16. smoking patients. 17. patients who in the opinion of the principal investigator are at risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial. 18. patients presenting contraindications to the rescue product, according to concerning summary of product characteristics (spc).